NMR spectroscopic study of the adduct formation and reactivity of homoleptic rare earth amides with alkali metal benzyl compounds, and the crystal structures of [Li(TMEDA)2][Nd{N(SiMe3)2}3(CH2Ph)] and [{Li(TMP)}2{Li(Ph)}]2

Dipolar Coupling as a Mechanism for Fine Control of Magnetic States in ErCOT-Alkyl Molecular Magnets

The design of molecular magnets has progressed greatly by taking advantage of the ability to impart successive perturbations and control vibronic transitions in 4fn systems through the careful manipulation of the crystal field. Herein, we control the orientation and rigidity of two dinuclear ErCOT-based molecular magnets: the inversion-symmetric bridged [ErCOT(μ-Me)(THF)]2 (2) and the nearly linear Li[(ErCOT)2(μ-Me)3] (3). The conserved anisotropy of the ErCOT synthetic unit facilitates the direction of the arrangement of its magnetic anisotropy for the purposes of generating controlled internal magnetic fields, improving control of the energetics and transition probabilities of the electronic angular momentum states with exchange biasing via dipolar coupling. This control is evidenced through the introduction of a second thermal barrier to relaxation operant at low temperatures that is twice as large in 3 as in 2. This barrier acts to suppress through-barrier relaxation by protecting the ground state from interacting with stray local fields while operating at an energy scale an order of magnitude smaller than the crystal field term. These properties are highlighted when contrasted against the mononuclear structure ErCOT(Bn)(THF)2 (1), in which quantum tunneling of the magnetization processes dominate, as demonstrated by magnetometry and ab initio computational methods. Furthermore, far-infrared magnetospectroscopy measurements reveal that the increased rigidity imparted by successive removal of solvent ligands when adding bridging methyl groups, along with the increased excited state purity, severely limits local spin-vibrational interactions that facilitate magnetic relaxation, manifesting as longer relaxation times in 3 relative to those in 2 as temperature is increased.

Optical properties and electronic structure of Eu(III) complexes with HMPA and TPPO

Two adducts of Eu(III) tris-hexofluoroacetylacetonate with HMPA (OP(N(CH₃)₂)₃, hexamethylphosphotriamide) and TPPO (OP(C₆H₅)₃, triphenylphosphine oxide) were studied by optical spectroscopy and quantum chemistry (DFT/TD-DFT). The structure of the higher occupied molecular orbitals (MO) of the two adducts determines differences in the position of the excitation band maximum of hfac ligands. According to the calculation data, all excited states are caused by the transition to 3 vacant π₄* MOs of hfac ligands. Optical spectra of absorption, excitation and luminescence are obtained and interpreted. The peculiarity of the HOMO-LUMO structure, the low value of the energy gap, and the broadened absorption region of hfac ligands compensate the low absorbance ability of the groups N(CH₃)₂ in a region of 220-360 nm for the adduct Eu(hfac)₃(HMPA)₂, reducing the luminescence intensity by only 5-10% relative to the adduct of the Eu(III) complex with TPPO ligands.

Heteroleptic complexes of cocaine/TMEDA with some f block metals: Synthesis, DFT studies, spectral, thermal, cytotoxicity and antimetastatic properties

A series of new three heteroleptic complexes of the general formula [Ln(Cn)(TMEDA)Cl(OH₂)]·2Cl·xH₂O, (where Ln = La(III), Er(III) and Yb(III), Cn = cocaine and TMEDA = N,N,N',N'-tetramethylethylenediamine) were synthesized, structurally characterized by elemental analysis, spectroscopic methods, molar conductivity and mass spectrometry. Thermal properties of the synthesized complexes and their kinetic thermodynamic parameters were studied. Theoretical calculations including geometry optimization, electronic structure and electronic and thermal energies were carried out using DFT and TD-DFT calculations at B3LYP/LANL2DZ level of theory and the different quantum chemical parameters were calculated. The in vitro antiproliferative activity of the newly synthesized complexes was assessed by MTT assay on MCF-7 and HepG-2 cancer cell lines. Yb(III) complex showed promising cytotoxic activity comparable to that of cisplatin on both cell lines with minimum effect on human normal cells. Further molecular mechanistic investigations showed that Yb(III) complex is an apoptotic inducer as it raises the caspase-3 and caspase-9 cellular level in the MCF-7 cell line. Furthermore, it showed an elevating effect on the level of the tumor suppressor nuclear proteins P21 and P27 concentrations in MCF-7 cells. Moreover, Yb(III) complex hindered the cellular scavenger system of the reactive oxygen species through reducing the glutathione peroxidase (GPx) cellular level imperiling MCF-7 cells by unmanageable oxidative stress. In addition to its cytotoxic effect, Yb(III) complex showed antimetastatic properties as it decreased the cellular levels of matrix metalloproteinases MMP-3 and MMP-9. These results showed that the Yb(III) complex is a promising cytotoxic metal-based agent that exerts its action through various molecular mechanisms with minimum effects on normal cells and with additional antimetastatic properties.

Synergic Deprotonation Generates Alkali-Metal Salts of Tethered Fluorenide-NHC Ligands Co-Complexed to Alkali-Metal Amides

Synergic combinations of alkali‐metal hydrocarbyl/amide reagents were used to synthesise saturated N‐heterocyclic carbene (NHC) ligands tethered to a fluorenide anion through deprotonation of a spirocyclic precursor, whereas conventional bases were not successful. The Li₂ derivatives displayed a bridging amide between two Li atoms within the fluorenide‐NHC pocket, whereas the Na₂ and K₂ analogues displayed extended solid‐state structures with the fluorenide‐NHC ligand chelating one alkali metal centre.

Reversible temperature-induced polymorphic phase transitions of [Y(OAr)3] and [Ce(OAr)3] (Ar = 2,6-tBu2-4-MeC6H2): interconversions between pyramidal and planar geometries

Exploring the balance of energetics between planar and pyramidal forms of [Y(O-2,6-^tBu₂-4-MePh)₃] and related complexes.